Member Info for Trickymatters

On the Imperial college site. REACT 1, biggest ever study so far is to be published next week- no specific date. This is on current prevalence using swab tests. REACT 2 is on antibody tests and was meant to be commenting on immunity in the original brief. Due 'very soon' according to an update for October 1st.

Had a sell on all day for 92p. Didn't go. And buying for £1.02. Ripping off their own customers. Nice :(

Biglad,
ODX are not comparable to VAL in any way shape or form. VAL are pre-clinical. They will only ever sell early concepts proved in stage 1 trials. They have been doing the same trials for 10 years. The directors got the sack. For every person who made money there, there's someone else who lost.
That isn't the case with a high growth company like Omega Diagnostics. Investors enter the arena at different stages of the company's development. It will probably never go back to being a penny share. Unlike VAL.

Lee city, 100 million was for non covid tests.

ONS survey says we need bigger prevalence surveys. All universities should be testing students regularly.

It mostly is anyway. But if we want new and big investors we have to keep restating the fundamentals now and then; restating the near and medium term catalysts for the sp and keep the trolls in check without letting them dominate the conversation. Right, have to go! Exciting times!

And that's the end of my helpful tips for today. I have to catch a train. GLA.

Cathay Pacific and United Airlines are starting trials in the states today. The UK government are making an announcement tomorrow about a to plan for a reduction of quarantine to 6 days.

I'm going out. Only way is up. Investors should really read and watch the investor presentations.
5 new generation tests. Now selling the best most accessible antibody test in the world to the UK government. Waiting for MHRA approval which is expected, to enable us to go commercial. Awaiting the next big immunity study. This started on August 24th with a cohort of 150,000. The previous study firmly recognised immunity lasting up to 4 months. The RTC self assessment test recognised immunity of 5 months- better than all the comparators- Roche, Abbott et al.
The antigen point of care test has done well in Heathrow trials and is now progressing to larger trials. Intended for inclusion in operation Moonshot with up to 3 million tests a day discussed in multiple British newspapers and wider media. Airport tests to reduce quarantine have the press speculating on retail prices for £150.00. Seems to much but that's what the Times, Telegraph and the Mail have said.
2.5 million capacity per week for the new year and 1 million by the end of 2020. Do the maths. This is going to explode.

The last presentation was Monday. Blimey, people are asking questions that are clearly covered in the presentations and RNS'.

The Guardian says 'the government are paying millions ' for them. We'll soon see when we get a fuller scope of the contract. We've already been told that ODX will be supplying at least 25% of all future government orders. When the MHRA approval comes in, which the Guardian reported yesterday is coming, we can sell commercially. That's why we will see huge investments showing later. People on level 2 are already seeing them.

Favourite sentence is where Lord Bethell is recognising massive export value alongside future UK sales. Second favourite is the recognition that the ABC19 test will have longterm value in helping to support the roll out of vaccines.
Calling all trolls! The government will now help you learn to read so you can keep up to date with progress of high growth, ethical, value firms like this and learn how to make money and stop losing money. Stop wasting your life. We don't care what you think!

I went out for a big walk with a friend today. We were discussing ODX a bit because she bought in on my suggestion. I came back to this news! I am loving ODX in October. It will get better and better now. The next big immunity report due anytime and when it lands we will rocket. What is great about this time period is that those who have followed the emerging evidence base now know we can expect nothing but good news.
5 tests. 3 of them are point of care which will do away with all the bottlenecks on test and trace. ODX are ramping up to 2.5 million tests a week. Tests will be sold to governments, NGOs around the world and commercially here and abroad. Best of the new generation tests and first out of the block. UK government gets a discount because of their prior investment. After that a more realistic pricing policy that will still blow the competition out of the water for affordability but can turn this company into a blockbuster!

Due on Thursday. They are thinking about 2 tests to reduce quarantine. Be nice if one was an antibody test and the other was Mologic's antigen test ;)

Guardian reports Shapps conference speech says more will be revealed 'in the coming days ' on this.

We know that there's been a story in the papers about Shapps making an announcement about airport testing this week. I wonder if we get the RTC contract first? Certainly the biggest antibody research so far (200,000) on immunity is due this week. Kicked off on August 24th for health workers who will definitely have been exposed multiple times. All the science is going in the right direction for investors on this. 20 weeks immunity already evident for us after the Ulster university report. We will start to get very solid news now. I don't think the mms can get away with this **** going forward. We'll get stronger volumes. Might be worth rethinking stop loss approach. This is a high value growth stock. Mms will take your shares and sell them high again minutes later.

Golferboy, thx mate. Me too. We all made a great choice.

No. ODX CEO didn't say he was hoping to become a mass producer for AVCT. He said we might help out if needed. ODX already have 5 tests. 3 of which are very close to market.

Feel sorry for all those who sold at 77p. Derampers to thank for that. Shame though. I would just buy back on any dips tomoz. We had significant news.
1. Ramping up capacity for the new year to 2.5 million a week
2. Mologic's antigen test has a great deal of interest already and will progress to larger trials after doing well in Heathrow trials. Nice 'Christmas present ' to look forward to there Colin thinks. Extra capacity earmarked for that. I guess for obvious reasons- will help save the aviation industry and will have the best returns.
3. RTC contract is expected 'very soon '
4. Mologic's poc antibody test is being prepared for commercial sales largely focused on international markets
5. We will be selling the RTC ABC19 test commercially in the UK and abroad and demand will be very high on the back of the credibility of government contracts
6. We will partner with Avacta if necessary to support the management of the pandemic
7. 65-70% profit margins will increase as we scale up
8. CD4 and HIV visitect market is up to £80 million earnings for medium term alongside branding out to other opportunities after covid such as TB.
Anything else?

Not sure what you're on about. Buying at 92.9, 93 on the book lined up.